<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35379357</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Print">2050-7771</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>10</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>04</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biomarker research</Title>
          <ISOAbbreviation>Biomark Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma.</ArticleTitle>
        <Pagination>
          <StartPage>17</StartPage>
          <MedlinePgn>17</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">17</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s40364-022-00357-5</ELocationID>
        <Abstract>
          <AbstractText>The advent of BTK inhibitors has changed the treatment of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The first-in-class BTK inhibitor ibrutinib has shown remarkable therapeutic effects and manageable toxicities in multiple clinical trials. The second-generation BTK inhibitors, including acalabrutinib and zanubrutinib, also show remarkable efficacies. However, using BTK inhibitors as monotherapies requires continuous treatment. Resistance to BTK inhibitors and severe side effects unavoidably occur during BTK inhibitor monotherapy, frequently resulting in treatment failure. The addition of the BCL2 inhibitor venetoclax to BTK inhibitor may improve the therapeutic effects and result in deeper responses, providing a potential fixed-duration treatment, especially for patients with CLL. In this review, by focusing on CLL and MCL, we discussed the rationale for the combinational use and summarized the current data on the combinations of BTK inhibitors and venetoclax in patients with CLL and MCL.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Lu</LastName>
            <ForeName>Xueying</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jianyong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. lijianyonglm@126.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China. lijianyonglm@126.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Pukou CLL Center, Nanjing, China. lijianyonglm@126.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, China. lijianyonglm@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miao</LastName>
            <ForeName>Yi</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0003-1799-1448</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. miaoyi1992@hotmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China. miaoyi1992@hotmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Pukou CLL Center, Nanjing, China. miaoyi1992@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Biomark Res</MedlineTA>
        <NlmUniqueID>101607860</NlmUniqueID>
        <ISSNLinking>2050-7771</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">BCL2 inhibitors</Keyword>
        <Keyword MajorTopicYN="N">BTK inhibitors</Keyword>
        <Keyword MajorTopicYN="N">Chronic lymphocytic leukemia</Keyword>
        <Keyword MajorTopicYN="N">Mantle cell lymphoma</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>5</Day>
          <Hour>5</Hour>
          <Minute>27</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35379357</ArticleId>
        <ArticleId IdType="pmc">PMC8981798</ArticleId>
        <ArticleId IdType="doi">10.1186/s40364-022-00357-5</ArticleId>
        <ArticleId IdType="pii">10.1186/s40364-022-00357-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4513941</ArticleId>
            <ArticleId IdType="pubmed">23782157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, et al.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4134521</ArticleId>
            <ArticleId IdType="pubmed">24881631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al.  Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4722809</ArticleId>
            <ArticleId IdType="pubmed">26639149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, et al.  Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30522969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al.  Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–2528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6325637</ArticleId>
            <ArticleId IdType="pubmed">30501481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, et al.  Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6908306</ArticleId>
            <ArticleId IdType="pubmed">31365801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Liu C, Tsui ST, Liu D. Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol. 2016;9(1):80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5010774</ArticleId>
            <ArticleId IdType="pubmed">27590878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9:21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4784459</ArticleId>
            <ArticleId IdType="pubmed">26957112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu D, Tang H, Wu J, Li J, Miao Y. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. J Hematol Oncol. 2021;14(1):40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7937220</ArticleId>
            <ArticleId IdType="pubmed">33676527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, et al.  Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739–745.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4528064</ArticleId>
            <ArticleId IdType="pubmed">26059948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, et al.  Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353–1363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6899718</ArticleId>
            <ArticleId IdType="pubmed">31512258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, et al.  Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34(3):787–798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7214263</ArticleId>
            <ArticleId IdType="pubmed">31628428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hampel PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Witzig TE, et al.  Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leuk Lymphoma. 2019;60(11):2712–2719.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6813846</ArticleId>
            <ArticleId IdType="pubmed">31014142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davids MS. Targeting BCL-2 in B-cell lymphomas. Blood. 2017;130(9):1081–1088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28724540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al.  Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7107002</ArticleId>
            <ArticleId IdType="pubmed">26639348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, et al.  Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(1):65–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6027999</ArticleId>
            <ArticleId IdType="pubmed">29246803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al.  Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–833.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5455685</ArticleId>
            <ArticleId IdType="pubmed">28095146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP, et al.  Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104(2):e68–e71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6355471</ArticleId>
            <ArticleId IdType="pubmed">30190341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen SS, Chang BY, Chang S, Tong T, Ham S, Sherry B, et al.  BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia. 2016;30(4):833–843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4832074</ArticleId>
            <ArticleId IdType="pubmed">26582643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Slinger E, Thijssen R, Kater AP, Eldering E. Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition. Leukemia. 2017;31(12):2601–2607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28462919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, et al.  BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35(13):1437–1443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5455463</ArticleId>
            <ArticleId IdType="pubmed">28418267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ondrisova L, Mraz M. Genetic and non-genetic mechanisms of resistance to BCR signaling inhibitors in B cell malignancies. Front Oncol. 2020;10:591577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7116322</ArticleId>
            <ArticleId IdType="pubmed">33154951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haselager MV, Kielbassa K, Ter Burg J, Bax DJC, Fernandes SM, Borst J, et al.  Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood. 2020;136(25):2918–2926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32603412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K, et al.  Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res. 2015;21(16):3705–3715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4537801</ArticleId>
            <ArticleId IdType="pubmed">25829398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng J, Isik E, Fernandes SM, Brown JR, Letai A, Davids MS. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia. 2017;31(10):2075–2084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5555835</ArticleId>
            <ArticleId IdType="pubmed">28111464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu P, Wang S, Franzen CA, Venkataraman G, McClure R, Li L, et al.  Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. Blood Cancer J. 2021;11(2):39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7893066</ArticleId>
            <ArticleId IdType="pubmed">33602908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kater AP, Slinger E, Cretenet G, Martens AW, Balasubramanian S, Leverson JD, et al.  Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia. Blood Adv. 2021;5(23):5410–5414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34555843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao X, Bodo J, Sun D, Durkin L, Lin J, Smith MR, et al.  Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. Br J Haematol. 2015;168(5):765–768.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25284608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Portell CA, Axelrod M, Brett LK, Gordon VL, Capaldo B, Xing JC, et al.  Synergistic cytotoxicity of ibrutinib and the BCL2 antagonist, ABT-199(GDC-0199) in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL): molecular analysis reveals mechanisms of target interactions. Blood. 2014;124(21):509.</Citation>
        </Reference>
        <Reference>
          <Citation>Li Y, Bouchlaka MN, Wolff J, Grindle KM, Lu L, Qian S, et al.  FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma. Oncogene. 2016;35(48):6223–6234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5102814</ArticleId>
            <ArticleId IdType="pubmed">27157620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hillmen P, Rawstron AC, Brock K, Munoz-Vicente S, Yates FJ, Bishop R, et al.  Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol. 2019;37(30):2722–2729.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6879312</ArticleId>
            <ArticleId IdType="pubmed">31295041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hillmen P, Boucher RH, Webster N, Dalal S, Brock K, Yates F, et al.  Continued long term responses to ibrutinib+venetoclax treatment for relapsed/refractory CLL in the blood cancer UK TAP CLARITY trial. Blood. 2020;136(Supplement 1):17–18.</Citation>
        </Reference>
        <Reference>
          <Citation>Niemann CU, Levin MD, Dubois J, Kersting S, Enggaard L, Veldhuis GJ, et al.  Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia. Blood. 2021;137(8):1117–1120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33027809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, et al.  Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial. JAMA Oncol. 2021;7(8):1213–1219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8193546</ArticleId>
            <ArticleId IdType="pubmed">34110383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, et al.  Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol. 2021;39(34):3853–3865.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8713593</ArticleId>
            <ArticleId IdType="pubmed">34618601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghia P, Allan JN, Siddiqi T, Kipps TJ, Kuss BJ, Opat S, et al.  First-line treatment with ibrutinib (Ibr) plus venetoclax (Ven) for chronic lymphocytic leukemia (CLL): 2-year post-randomization disease-free survival (DFS) results from the minimal residual disease (MRD) cohort of the phase 2 CAPTIVATE study. Blood. 2021;138(Supplement 1):68.</Citation>
        </Reference>
        <Reference>
          <Citation>Allan JN, Wierda WG, Siddiqi T, Kipps TJ, Jacobs R, Opat S, et al.  Primary analysis of the fixed-duration cohort from the phase 2 CAPTIVATE study of first-line ibrutinib+venetoclax for chronic lymphocytic leukemia/small lymphocytic lymphoma. EHA Library. 2021;324555:S147.</Citation>
        </Reference>
        <Reference>
          <Citation>Thompson PA, Wang Y, Keating MJ, Ferrajoli A, Jain N, Peterson CB, et al.  Venetoclax consolidation in patients with high-risk CLL who have been on ibrutinib more than a year achieves a high rate of undetectable minimal residual disease. Blood. 2021;138(Supplement 1):3723.</Citation>
        </Reference>
        <Reference>
          <Citation>Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, et al.  Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378(13):1211–1223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29590547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Handunnetti SM, Anderson MA, Burbury K, Hicks RJ, Birbirsa B, Bressel M, et al.  Three year update of the phase II ABT-199 (venetoclax) and ibrutinib in mantle cell lymphoma (AIM) study. Blood. 2019;134(Supplement 1):756.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang M, Ramchandren R, Chen R, Karlin L, Chong G, Jurczak W, et al.  Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. J Hematol Oncol. 2021;14(1):179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8556975</ArticleId>
            <ArticleId IdType="pubmed">34717692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scarfo L, Heltai S, Albi E, Scarano E, Schiattone L, Farina L, et al.  Minimal residual disease-driven treatment intensification by sequential addition of ibrutinib to venetoclax in relapsed/refractory chronic lymphocytic leukemia: results of the monotherapy and combination phases of the IMPROVE study. Blood. 2020;136(Supplement 1):21–22.</Citation>
        </Reference>
        <Reference>
          <Citation>Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, et al.  Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019;133(10):1011–1019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6405333</ArticleId>
            <ArticleId IdType="pubmed">30530801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, et al.  Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood. 2014;123(12):1957–1960.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3962169</ArticleId>
            <ArticleId IdType="pubmed">24652965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharman JP, Brander DM, Mato AR, Ghosh N, Schuster SJ, Kambhampati S, et al.  Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. Lancet Haematol. 2021;8(4):e254–ee66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33631112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Timofeeva N, Gandhi V. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results. Blood Cancer J. 2021;11(4):79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8085243</ArticleId>
            <ArticleId IdType="pubmed">33927183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–1110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24401022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al.  Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–1291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8151619</ArticleId>
            <ArticleId IdType="pubmed">32305093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, et al.  A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. Blood Adv. 2019;3(10):1568–1573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6538868</ArticleId>
            <ArticleId IdType="pubmed">31101647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kater AP, Kersting S, van Norden Y, Dubois J, Dobber JA, Mellink CH, et al.  Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL. Blood Adv. 2018;2(24):3566–3571.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6306887</ArticleId>
            <ArticleId IdType="pubmed">30552161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rogers KA, Huang Y, Ruppert AS, Abruzzo LV, Bhat SA, Hoffman C, et al.  Three-year follow-up from a phase 2 study of combination obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia. Blood. 2020;136(Supplement 1):9–10.</Citation>
        </Reference>
        <Reference>
          <Citation>Huber H, Edenhofer S, von Tresckow J, Robrecht S, Zhang C, Tausch E, et al.  Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia. Blood. 2022;139(9):1318–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">35108374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Gouill S, Morschhauser F, Chiron D, Bouabdallah K, Cartron G, Casasnovas O, et al.  Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. Blood. 2021;137(7):877–887.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33181832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davids MS, Lampson BL, Tyekucheva S, Crombie JL, Ng S, Kim AI, et al.  Updated safety and efficacy results from a phase 2 study of acalabrutinib, venetoclax and obinutuzumab (AVO) for frontline treatment of chronic lymphocytic leukemia (CLL) Blood. 2020;136(Supplement 1):20–21.</Citation>
        </Reference>
        <Reference>
          <Citation>Woyach JA, Blachly JS, Rogers KA, Bhat SA, Grever MR, Kittai AS, et al.  Acalabrutinib in combination with venetoclax and obinutuzumab or rituximab in patients with treatment-naïve or relapsed/refractory chronic lymphocytic leukemia. Blood. 2020;136(Supplement 1):16–18.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang M, Robak T, Maddocks KJ, Phillips T, Smith SD, Gallinson D, et al.  Safety and efficacy of acalabrutinib plus venetoclax and rituximab in patients with treatment-naïve (TN) mantle cell lymphoma (MCL) Blood. 2021;138(Supplement 1):2416.</Citation>
        </Reference>
        <Reference>
          <Citation>Soumerai JD, Mato AR, Dogan A, Seshan V, Joffe E, Flaherty K, et al.  Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence. Blood. 2021;138(Supplement 1):3753.</Citation>
        </Reference>
        <Reference>
          <Citation>Kumar A, Soumerai JD, Abramson JS, Batlevi CL, Chadha P, Dogan A, et al.  Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen) Blood. 2021;138(Supplement 1):3540.</Citation>
        </Reference>
        <Reference>
          <Citation>Woyach JA, Blachly JS, Rogers KA, Bhat SA, Jianfar M, Lozanski G, et al.  Acalabrutinib plus obinutuzumab in treatment-naive and relapsed/refractory chronic lymphocytic leukemia. Cancer Discov. 2020;10(3):394–405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8176161</ArticleId>
            <ArticleId IdType="pubmed">31915195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson PA, Levy V, Tam CS, Al Nawakil C, Goudot FX, Quinquenel A, et al.  Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol. 2016;175(3):462–466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27611233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang C, Deng L, Karr MA, Wen Y, Wang Q, Perimbeti S, et al.  Chronic comorbid conditions among adult cancer survivors in the United States: results from the National Health Interview Survey, 2002-2018. Cancer. 2022;128(4):828–838.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8792209</ArticleId>
            <ArticleId IdType="pubmed">34706057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, et al.  A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889–3897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6925383</ArticleId>
            <ArticleId IdType="pubmed">31761945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, et al.  Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102(10):1796–1805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5622864</ArticleId>
            <ArticleId IdType="pubmed">28751558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi T, Jiang C, Zhu C, Wu F, Fotjhadi I, Zarich S. Insurance disparity in cardiovascular mortality among non-elderly cancer survivors. Cardiooncology. 2021;7(1):11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7980587</ArticleId>
            <ArticleId IdType="pubmed">33743837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yabroff KR, Han X, Song W, Zhao J, Jemal A, Zheng Z. Association of cancer history and medical financial hardship with mortality in the United States. J Clin Oncol. 2020;38(29_suppl):86.</Citation>
        </Reference>
        <Reference>
          <Citation>Knight TG, Aguiar M, Robinson M, Martin A, Chen T, Bose R, et al.  Financial toxicity intervention decreases mortality in high risk hematologic malignancy patients. Blood. 2020;136(Supplement 1):14–15.</Citation>
        </Reference>
        <Reference>
          <Citation>Kater A, Owen C, Moreno C, Follows G, Munir T, Levin MD, et al.  Fixed-duration ibrutinib and venetoclax (I+V) versus chlorambucil plus obinutuzumab (CLB+O) for first-line (1L) chronic lymphocytic leukemia (CLL): primary analysis of the phase 3 GLOW study. EHA. Library. 2021;330172:LB1902.</Citation>
        </Reference>
        <Reference>
          <Citation>Munir T, Moreno C, Owen C, Follows GA, Benjamini O, Janssens A, et al.  First prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of CLL in elderly or unfit patients: the Glow study. Blood. 2021;138(Supplement 1):70.</Citation>
        </Reference>
        <Reference>
          <Citation>Michallet A-S, Quinquenel A, Letestu R, Le Garff-Tavernier M, Subtil F, Elsensohn M-H, et al.  Preliminary results of the filo phase 2 trial for untreated fit patients with intermediate risk chronic lymphocytic leukemia comparing ibrutinib plus venetoclax (IV) versus FCR. Blood. 2021;138(Supplement 1):641.</Citation>
        </Reference>
        <Reference>
          <Citation>Kater AP, Wu JQ, Kipps T, Eichhorst B, Hillmen P, D'Rozario J, et al.  Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. J Clin Oncol. 2020;38(34):4042–4054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7768340</ArticleId>
            <ArticleId IdType="pubmed">32986498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furstenau M, Eichhorst B. Novel agents in chronic lymphocytic leukemia: new combination therapies and strategies to overcome resistance. Cancers (Basel) 2021;13(6):1336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8002361</ArticleId>
            <ArticleId IdType="pubmed">33809580</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
